Surgical heart valve therapy market under pressure
With advancement and expansion of THV (transcatheter heart valve) therapy, the SHV (surgical heart valve) therapy business has come under pressure, and the market growth has slowed down. However, the market is forecast to register growth despite developed markets witnessing growth in TAVR procedures.
Edwards Lifesciences (EW) is focused on advancing its surgical heart valve business through an advancement in its core aortic leadership position, development of transformational surgical therapies for mitral valve patients, and expansion across the markets with an underserved patient population. According to Edwards Lifesciences, the surgical heart valve opportunity is worth ~$1.8 billion.
Valvular heart diseases: Aortic stenosis market dynamics
Some of the macro trends such as an aging population support the growth of people suffering from heart disease. Despite the growth of THV procedures in developed countries leading to weakness in SHV procedure growth, Edwards Lifesciences expects the global SHV market to grow at a gradual pace.
The surgical mitral procedures are a key opportunity area and are expected to match the surgical aortic procedures market by 2023. While such cases are declining in developed markets and older patients, more younger patients and an emerging market population are undergoing surgical aortic procedures for the treatment of AS (aortic stenosis).
Medtronic (MDT), Abbott Laboratories (ABT), and Boston Scientific (BSX) are other major players offering surgical heart valve therapies to patients around the globe. Investors keen on investing in the growth potential of Edwards Lifesciences while diversifying the risks can invest in the Vanguard S&P 500 ETF (VOO), which holds ~0.10% of its total portfolio in Edwards Lifesciences.